Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Immunogen, Inc. Patents
Assignee:
Immunogen, Inc.
Address:
Cambridge, MA
No. of patents:
83
Patents:


1 2










Patent Number Title Of Patent Date Issued
RE39151 Process for the preparation and purification of thiol-containing maytansinoids June 27, 2006
The present invention provides a process for the preparation and purification of thiol-containing maytansinoids comprising the steps of: (1) reductive hydrolysis of a maytansinoid C-3 ester with a reducing agent selected from the group consisting lithium trimethoxyaluminum hydride (L
8563700 Synergistic effects October 22, 2013
The present invention encompasses a combination of at least one conjugate and one or more chemotherapeutic agent(s) which when administered exerts an unexpectedly enhanced therapeutic effect. The therapeutic effectiveness of the combination is greater than that of the conjugate alone
8563509 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates l October 22, 2013
The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more
8268617 Anti-IGF-I receptor antibodies, DNAs, vectors, host cells and genetic constructs September 18, 2012
DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I recept
8236319 Cross-linkers and their uses August 7, 2012
Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
8198417 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates l June 12, 2012
The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more
8163888 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates l April 24, 2012
The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more
8137669 Elimination of heterogeneous or mixed cell population in tumors March 20, 2012
Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population
8119787 Molecular tools for manufacturing anti-CD33 antibodies and fragments February 21, 2012
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these ant
8093358 Methods of treatment using anti-erbb antibody-maytansinoid conjugates January 10, 2012
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-mayt
8088387 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates l January 3, 2012
The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more
8034904 Anti-IGF-I receptor antibody October 11, 2011
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substant
8012978 Prodrugs of CC-A1065 analogs September 6, 2011
The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the protecting group confers enhanced water solubility upon the prodrug, and in which the prodr
8012485 Drug conjugate composition September 6, 2011
The invention provides a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human the r
7989598 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates l August 2, 2011
The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more
7985842 Anti-IGF-I receptor antibody July 26, 2011
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substant
7906545 Prodrugs of CC-1065 analogs March 15, 2011
Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in whic
7851432 Cytotoxic agents comprising new maytansinoids December 14, 2010
New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the .alpha.-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to
7834155 CA6 antigen-specific cytotoxic conjugate and methods of using the same November 16, 2010
Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed ar
7811572 Process for preparing purified drug conjugates October 12, 2010
The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.
7655661 Prodrugs of CC-1065 analogs February 2, 2010
Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in whic
7655660 Prodrugs of CC-1065 analogs February 2, 2010
Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in whic
7601354 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents October 13, 2009
The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconj
7598290 Cytotoxic agents comprising new C-2 modified taxanes October 6, 2009
The invention relates to taxanes and to novel cytotoxic agents comprising taxanes and their therapeutic use as a result of delivering the taxanes to a specific cell population in a targeted fashion by chemically linking the taxane to a cell binding agent.
7585857 Cytotoxic agents comprising taxanes and their therapeutic use September 8, 2009
A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a phar
7557189 Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same July 7, 2009
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these ant
7550609 Cytotoxic agents comprising taxanes and their therapeutic use June 23, 2009
A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a phar
7538195 Anti-IGF-I receptor antibody May 26, 2009
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substant
7528130 Cytotoxic agents comprising taxanes and their therapeutic use May 5, 2009
A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a phar
7514080 Drug conjugate composition April 7, 2009
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administeri
7501120 Drug conjugate composition March 10, 2009
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administeri
7495114 Cytotoxic agents containing novel potent taxanes and their therapeutic use February 24, 2009
Included within the scope of the present invention are potent taxanes and taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selected cell populatio
7494649 Drug conjugate composition February 24, 2009
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administeri
7476669 Cytotoxic agents comprising taxanes and their therapeutic use January 13, 2009
A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a phar
7473796 Cytotoxic agents comprising new maytansinoids January 6, 2009
New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the .alpha.-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to
7449450 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes an November 11, 2008
Novel polypeptides having anti-apoptotic activity, and methods of screening for such novel polypeptides having anti-apoptotic activity, and polynucleotides encoding such polypeptides; Compounds that regulate or modulate apoptosis and/or anti-apoptotic activity, such as compounds havi
7432088 Methods for the production of ansamitocins October 7, 2008
A process of the large-scale fermentation of a highly productive ansamitocin-producing strains. A method for isolating crude ansamitocins. A method for purifying ansamitocins.
7414073 Cytotoxic agents containing novel potent taxanes and their therapeutic use August 19, 2008
Included within the scope of the present invention are potent taxanes and taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selected cell populatio
7411063 Process for preparation of maytansinol August 12, 2008
The present invention describes the preparation of maytansinol by methods that minimize processing steps, and reduce solvent volumes, making the process more efficient, and scaleable. This process comprises a step of converting bridged acetals of maytansinol to maytansinol. The simplifie
7390898 Cytotoxic agents containing novel potent taxanes and their therapeutic use June 24, 2008
Included within the scope of the present invention are potent taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selected cell populations comprisin
7388026 Prodrugs of CC-1065 analogs June 17, 2008
Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in whic
7374762 Drug conjugate composition May 20, 2008
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administeri
7368565 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents May 6, 2008
The present invention discloses a one-step process for the production of cytotoxic conjugates of maytansinoids and cell binding agents. Maytansinoids having a disulfide linker that bears a reactive moiety are linked to cell binding agents, such as antibodies, without prior modificati
7358088 Peptides and compositions which modulate apoptosis April 15, 2008
The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated
7342110 Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same March 11, 2008
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these ant
7329760 CC-1065 analog synthesis February 12, 2008
Improved synthesis of seco(-)CBI (5-hydroxy-3-amino-1-[S]-(chloromethyl)-1,2-dihydro-3H-benz(e)indole): ##STR00001## and improved syntheses therefrom of a wide variety of CC-1065 analogs that comprise a cyclopropabenzidole (CBI) alkylating moiety, and which are collectively DC1 and
7303749 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents December 4, 2007
The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconj
7301019 Method for the preparation of maytansinoid esters November 27, 2007
Improved processes for the preparation and purification of maytansinoid esters, especially thiol and disulfide-containing maytansinoids are described. In one aspect the process comprises a process of making a maytansinoid ester comprising forming an anion of maytansinol or a maytansi
7276499 Cytotoxic agents comprising taxanes and their therapeutic use October 2, 2007
A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a phar
7217819 Cytotoxic agents comprising taxanes and their therapeutic use May 15, 2007
A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a phar
1 2

 
 
  Recently Added Patents
Method for execution upon processing of at least one histological sample
Semiconductor device including multi-chip
Light powered hearing aid
(4931
Method for transmitting an electronic short message to multiple receivers
Use of a high-oleic and high-tocol diet in combination with a non-tocol antioxidant for improving animal meat quality
Moving picture decoding device and moving picture decoding method
  Randomly Featured Patents
Modular power control system with multipin connectors and airflow conrol module
Device for locking a switch blade with a stock rail
Pipe gasket and method of installation
Production method of stator blade and turbo-molecular pump with the stator blade
Fast food containing and serving device
Cover for a box of electric contacts such as switches, push button, sockets and the like
Topical glutathione formulations for menopausal skin
Apparatus and method for detecting leaks in welded heat exchanger plates
Multifunctional timepiece module with application specific printed circuit boards
Combined primary and spare submerged scraper conveyor arrangement